Introduction
Chronic myelomonocytic leukemia (CMML) is a genetically diverse hematologic malignancy characterized by cytopenias with or without leukocytosis, marrow dysplasia, monocytosis, splenomegaly, and a propensity to transform to acute myeloid leukemia. 1 Due to a series of genetic abnormalities that span across a wide array of biological processes, CMML is among the most aggressive and poorly understood chronic myeloid malignancies with a 3-year overall survival approximating 20%. Based on WHO criteria, patients are subclassified by bone marrow myeloblast percentage into CMML-1 (5%-10%) and CMML-2 (11%-19%) 7 categories.
In addition to CMML, Juvenile Myelomonocytic Leukemia (JMML), a rare pediatric hematologic malignancy, is included among the MDS/MPN group. Although the median age of onset is 2 years, it shares many clinical features of CMML and has a poor overall prognosis. The presence of monocytosis in JMML is associated with selective hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF). This phenomenon, and hallmark of the disease, was first described in 1991 by hematopoietic colony formation assays (CFAs) 8 and shown to occur in small CMML cohorts of 3-7 patients. [8] [9] [10] Although GM-CSF, interleukin (IL)-3 and IL-5 regulate monocytes through a common β -chain, JMML concentration-dependent hypersensitivity is selective for GM-CSF. 8 Each of the myeloid-regulating cytokines within the GM-CSF receptor (GM-CSFR) family bind specific α -chains, but share a common
For personal use only. on April 3, 2017 . by guest www.bloodjournal.org From necessary for activation. 11 In the case of GM-CSF, the α -chains and β -chains combine to form its active heterododecomer complex, allowing for association with Janus kinase 2 (JAK2). 12 Receptor interaction and phosphorylation by JAK2 are required for initiating intracellular signaling events that lead to signal transducer and activator of transcription (STAT)-5, Ras, and phosphatidylinositol-3 kinase activation. 13, 14 Because GM-CSF signaling is critical for monocyte differentiation and survival, targeting GM-CSF in the therapeutics of JMML in vitro and Acute Myeloid Leukemia (AML) in vivo has been reported with varying degrees of success. 15, 16 Considering the mutational and clinical variability among CMML patients and potential for therapeutic intervention, GM-CSF-dependent hypersensitivity should be explored further. Using primary samples from CMML patients, hypersensitivity to GM-CSF was determined by phospho-specific STAT5 flow cytometry (pSTAT5-flow) and by hematopoietic CFAs. The clinical characteristics and impact of known recurrent mutations on GM-CSF-dependent hypersensitivity was also investigated. Cytokine specificity was determined by comparing pSTAT5 in response to GM-CSF, IL-3 and G-CSF and by using a novel, humaneered TM monoclonal antibody against GM-CSF (KB003, KaloBios Pharmaceuticals). This humanized antibody directly binds to the cytokine, which interrupts binding to its cognate receptor. In this preclinical study, our utilization of this GM-CSF-specific monoclonal antibody provides rationale for future clinical development. Pre-clinical studies with JAK2 inhibitors also indicate the importance of the GM-CSF/JAK/STAT5 axis on cell survival in vitro in CMML.
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Methods

Primary patient samples
Determination of pSTAT5 levels
Flow cytometry for the detection of pSTAT5 was examined after treatment with GM-CSF, IL-3 and G-CSF using methods established in JMML. 10, 17, 18 For this assay, BMMNCs from CMML patients and healthy controls were suspended in prewarmed StemSpan H3000 with 10% FBS at a concentration of 1-2 million cells/ml for 2 hours at 37ºC. Cells were washed and suspended in pre-warmed RPMI devoid of cytokines or serum for 1 hour at 37ºC. The human MO7e cell line was used as a positive control for each assay and was obtained as a generous gift from the laboratory of Ken Zuckerman. 
Sequencing of patient samples
Known mutations in CMML were examined with detailed information provided in supplemental methods.
20,21
DNA was unavailable in two patients so this subset analysis was performed on 18 of the 20 patients studied for GM-CSF hypersensitivity by pSTAT5-flow (supplemental Table 1 ). Genes examined included NRAS, KRAS, C-CBL, JAK2, RUNX1, SRSF2, ASXL1, EZH2, and TET2.
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Survival assay with KB003
Ten primary, frozen CMML samples were defrosted in prewarmed StemSpan H3000
with 10% FBS at a concentration of 1-2 million cells/ml for 2 hours at 37ºC. MO7e was used as a positive control. Specific details about the survival assay are provided in supplemental methods.
Treatment with JAK2 inhibitors
The doses of ruxolitinib, SD-1029, CYT-387, and TG-101348 were selected based on previously published reports.
22-25 After six frozen BM-MNCs were thawed as described above, samples were pretreated with their respective JAK2 inhibitor for 1 hr. Next, cells were stimulated with 10ng/ml of GM-CSF for 15 minutes and fixed, permeabilized, and tested for GM-CSF-dependent pSTAT5, as described above. To determine the impact of JAK2 inhibition on CMML BM-MNC viability, 5 CMML BM-MNCs were treated with class-selective inhibitors for 48 hours and the death of BM-MNC subsets tested, as described in supplemental methods using the DAPI viability assay. 
GM-CSF receptor density
BM-MNCs from 15 CMML patients were stained with CD34-PerCPcy5.5, CD38-PECy7, CD11b-Pacific Blue, CD33-PE, and CD14 APC Cy7 to determine myeloid subpopulations. DAPI was used to exclude non-viable cells, and CD116-PE (BD Biosciences # 551373) was used to determine the density of GM-CSF on a per cell basis. 28 Flow cytometry calibration beads and Quantum MESF detection beads were used to account for daily cytometer variation and standardization of mean fluorescent intensity, respectively. 
Statistical analysis
Results
CMML displays GM-CSF-dependent hypersensitivity
Hypersensitivity testing to GM-CSF signaling is a standard criterion for the diagnosis of JMML. 1 In an effort to facilitate efficient clinical testing, pSTAT5-flow has been developed and found to correlate with GM-CSF hypersensitivity by CFAs. 10 In a previous study of five CMML patient samples, pSTAT5 activation in response to low dose GM-CSF suggested that cytokine hypersensitivity is a feature of CMML. 
Clinical characteristics of GM-CSF hypersensitive patients.
CMML patient characteristics were compared to the percentage and FI of pSTAT5-positive cells as continuous variables and results are shown in Table 1 . We found that Table 1 defines individual mutations in this cohort. Comparing patients without a mutation (n=5) to those with a mutation (n=13), there was no difference in percent or FI of pSTAT5 at a dose of 0.1 ng/ml of GM-CSF (Table 1) .
Levels of GM-CSF response were also similar among patients with mutations in RUNX1, splicing, and epigenetic modifiers when compared to the cohorts without these mutations, as shown in Table 1 . However, the mean percentage of pSTAT5 positive cells relative to maximal response (1.0) to GM-CSF in patients with a signaling mutation was 0.5 compared to 0.2 in those without a signaling mutation (p=0.037). A difference in FI was also observed (mean of 0.3 with signaling mutations versus 0.1 no signaling mutations, p=0.05) in this cohort. Signaling mutations were associated with a greater responsive to GM-CSF 1 and 10 ng/ml, as shown in Figure 1D indicating that this mutation class intensifies the pSTAT5 response in CMML. To confirm the selectivity to GM-CSF, pSTAT5 ( Figure 2A ) and CFA ( Figure 2B) response was also examined after treatment with IL-3 and G-CSF using BM-MNCs from CMML samples and healthy controls. In the patient samples tested, significantly more colonies formed in the presence of GM-CSF compared to IL-3 and G-CSF.
Furthermore, the morphological appearance of colonies in response to GM-CSF was distinct ( Figure 2B ). Large, compact, and organized colonies were present after GM-CSF treatment, whereas, the colonies induced by IL-3 were diffuse and less organized.
Colonies induced by G-CSF were small and rarely detected. Essentially all colonies KB003 is an antibody to GM-CSF that interacts with a previously defined epitope, recognized by the LMM102 antibody. 26 The antibody was humanized for future therapeutic application by KaloBios Pharmaceuticals. Surface plasmon resonance analysis was used to compare binding kinetics for the interaction of KB003 or the chimeric LMM102 reference antibody to glycosylated human GM-CSF. 27 KB003 or the LMM102 reference antibody was captured onto the Biacore chip surface, and GM-CSF was used as the analyte. Kinetic constants were determined in two independent experiments (Table 2) . GM-CSF is a monomeric molecule in solution; therefore, this assay determines the monovalent affinity for binding of GM-CSF to antibody. Similar association constants, dissociation constants, and calculated affinities were found using the two related antibodies (LMM102 and KB003).
Next, the KB003 antibody was used to determine its ability to neutralize GM-CSF activity. This assay was performed using the human U937 cell line, which has been reported to secrete IL-8 in response to GM-CSF treatment. 29 A dose-dependent reduction in IL-8 secretion was evident after incubation with KB003 ( Figure 3A ), For personal use only. on April 3, 2017. by guest www.bloodjournal.org From indicating that the antibody is functional. KB003 inhibited GM-CSF activity with a mean IC 50 from three independent assays of 48.2 ng/ml.
The ability of KB003 to neutralize GM-CSF-dependent survival of MO7e was determined. Cells were cultured in the presence or absence of GM-CSF with or without KB003. A significant dose-dependent increase in the percentage of apoptotic cells was seen in the presence of all doses of GM-CSF tested when KB003 was added at doses ranging from 1 to 10 μg/ml ( Figure 3B ).
To determine whether KB003 is capable of reducing CMML cells in vitro, primary BM-MNCs from 10 patients with GM-CSF hypersensitivity were used for hematopoietic CFAs. These assays were performed in the presence of GM-CSF (10 ng/ml) with increasing doses of KB003 (n=7) compared to DMSO control. Hematopoietic colonies were dose-dependently decreased with KB003 ( Figure 3C ). These quantitative differences were accompanied by qualitative differences in colony morphology, as colonies generated in the presence of KB003 were less organized and more diffuse than controls ( Figure 3D ). In contrast to the percentage of some myeloid populations expressing this receptor, the molecular density was indistinguishable in patients and controls within all myeloid subsets. Importantly, there was no evident difference in CD116 FI among immature monocytes, defined as CD33+/CD14+ ( Figure 4C ). These results suggest that GM-CSFR overexpression does not mediate the GM-CSF hypersensitivity in CMML.
GM-CSFR density is not increased in our CMML
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Sensitivity of myeloid subsets to KB003 and JAK2 inhibition.
The sensitivity of myeloid subpopulations was examined using KB003. Because CD38+ cells are reported to be the most pSTAT5 responsive in JMML 10 , this population was specifically examined for sensitivity to KB003. BM-MNCs were micro-cultured in the presence of KB003, FBS, and increasing doses of GM-CSF. After 48 hours, these cultures were analyzed using a flow cytometry myeloid panel and DAPI to determine
viability. The percentage of distinct myeloid subpopulations within the viable gate was normalized to cells cultured without KB003 ( Figure 5A ).
As expected, the immature monocytes were more sensitive to KB003 at all doses of GM-CSF ( Figure 5B ) compared to CD33+/CD14-cells. Subdividing the CD33+ cells into those that are CD38+ versus CD38-, we found that the CD33+/CD38+ were extremely sensitive to GM-CSF inhibition by KB003 with a significant decrease in proportion of viable cells (P<0.05) after treatment with 10 and 100 µg/mL of KB003 ( Figure 5C ). In contrast, CD33+/CD38-cells were less sensitive to drug suppression.
Because the CMML stem cell population is currently unknown, we compared KB003 sensitivity in CD34+/CD38+ cells and found no decrease in viable cells in response to KB003 treatment ( Figure 5D ). However, insufficient viable cells in the CD34+/CD38-population were available for analysis. 
Discussion
Nearly all JMML patients exhibit dose-dependent activation of pSTAT5 in response to GM-CSF. This cytokine-specific response is exclusively present in JMML compared to healthy controls and other pediatric MPNs indicating that it is critical for disease pathogenesis. Preclinical studies using diphtheria-conjugated GM-CSF have justified targeting this pathway in a clinical trial in AML. 16 Unfortunately, the diphtheriatoxin conjugate demonstrated an unacceptable hepatic toxicity profile that prevented further clinical evaluation. were both associated with the degree of GM-CSF pSTAT5. Our data suggests that these divergent molecular events may mediate responses that converge within the GM-CSF/pSTAT5 pathway by an unknown mechanism that correlates with disease progression.
Even in JMML, the mechanism by which GM-CSF-dependent pSTAT5 sensitivity occurs is unknown and under investigation. The precise interaction between mutations in proteins involved in Ras signaling, such as PTPN11, NRAS, and CBL, with pSTAT5 activation is unclear. 33 The matter is likely more complicated in CMML considering its genetic heterogeneity, and thus requires comprehensive annotation of the mutations to unravel. However, we did consider the possibility that GM-CSFR density may be increased in CMML. Aberrant receptor expression was not detected on any of the inhibition, which is consistent with JMML data. 10 However, it is noted that the CD34 positive subset was insensitive to GM-CSF signal inhibition suggesting that this strategy is unlikely to yield a curative therapeutic as it is possible that the CD34 subset includes, at least in part, the leukemia initiating cell. It remains unclear if suppression of this myeloid progenitor population is necessary to avoid risk of AML transformation or chronic anemia. Since these two events represent the major source of morbidity and mortality in this patient population, future therapeutic trials should incorporate biomarker analysis for the CD34 population. Taken together, however, we believe that the GM-CSF signaling cascade is an excellent CMML-specific therapeutic target, and clinical studies are ongoing to test KB003 and JAK2 inhibitor therapeutic activity in this disease. was identified (n=7). GM-CSF dependent pSTAT5 response was compared to those without a signaling mutation (n=11). Viability is relative to the DMSO drug vehicle control and was measured using a viability stain (DAPI) by flow cytometry. For personal use only. on April 3, 2017. by guest www.bloodjournal.org From
